Medium Risk

Zota Health Care Limited

Manufacturing & Marketing of Pharmaceutical products

CIN: L24231GJ2000PLC038352 FY: 2024-2025 Revenue: ₹257.3 Cr
5.4
ESG Risk
Score /10
Compliance RiskEpr ExposureGovernance Risk

Risk Breakdown

GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.0
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
3.0
Governance Risk
6.0

Financial Exposure

Est. Compliance Cost₹0–2 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated20.5 T

Governance

Anti-Corruption PolicyUnknown
Conflict of Interest PolicyYes
BRSR AssuranceNone
Assurance Provider

Double Materiality

Financial Materiality5.4
Impact Materiality4.6
QuadrantFinancially Material

Supply Chain

MSME Sourcing0.3%
Lifecycle AssessmentNo
Product ReclaimYes

Material Risks

e-waste

AI Risk Summary

**ZOTA HEALTH CARE LIMITED – FINANCIAL RISK SUMMARY** Zota Health Care faces critical compliance exposure under SEBI BRSR Core Expansion requirements, with a perfect 10.0/10 compliance risk score indicating material disclosure and governance gaps that could trigger enforcement action or delisting risk for listed-tier classification. The company's undefined EPR (Extended Producer Responsibility) applicability creates contingent liability exposure; pharmaceutical packaging typically falls under Schedule IV of India's Plastic Waste Management Rules, potentially requiring take-back infrastructure investment of ₹1–2 crore if triggered. Despite zero reported Scope 1 & 2 emissions, the omission of quantified GHG data across ₹257.3 crore revenue operations suggests incomplete measurement systems rather than genuinely zero impact, creating audit and regulatory scrutiny risk. Immediate priority: validate EPR applicability, establish certified emission accounting protocols, and close BRSR disclosure gaps to avoid regulatory penalties under India's mandatory environmental reporting framework.

Source: Zota Health Care Limited BRSR Filing, FY 2024-2025. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.

← Back to ESG Quotient Dashboard Share on LinkedIn Browse all companies →